Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 6/2020

01-06-2020 | Glioblastoma | Original Article

Calpain suppresses cell growth and invasion of glioblastoma multiforme by producing the cleavage of filamin A

Authors: Lin Cai, Qun Li, Wenfeng Li, Chengde Wang, Ming Tu, Zhangzhang Zhu, Zhipeng Su, Xianghe Lu

Published in: International Journal of Clinical Oncology | Issue 6/2020

Login to get access

Abstract

Background

Filamin A is the most widely expressed isoform of filamin in mammalian tissues. It can be hydrolyzed by Calpain, producing a 90-kDa carboxyl-terminal fragment (ABP90). Calpeptin is a chemical inhibitor of Calpain, which can inhibit this effect. It has been shown that ABP90 acts as a transcription factor which is involved in mediating cell signaling. However, the significance of ABP90 and its clinical signature with underlying mechanisms have not been well studied in glioblastoma multiforme (GBM).

Methods

ABP90 protein was measured in 36 glioma patients by Western blot. Human GBM cell lines U87 and A172 were used to clarify the precise role of ABP90. CCK-8 assay was used to analyze the cell viability. Transwell invasion assay and wound healing assay were used to analyze the migration and invasion. Expression of matrix metalloproteinase 2/tissue inhibitors of metalloproteinase 2 (MMP2/TIMP2) protein was analyzed by Western blot.

Results

ABP90 protein expression was lower in GBM tissues. The patients with low ABP90 protein expression had a shorter OS time (p = 0.046). After being treated with Calpain, the expression of ABP90 was upregulated, which led to a decline of cell viability, enhanced the efficacy of temozolomide and restrained the cell invasion. Calpeptin could inhibit the effect. The mechanism might be involved in the balance of MMP2/TIMP2.

Conclusions

Our present data suggest that ABP90 expression is a significant prognostic factor and may play an important role in cell viability, chemotherapeutic sensitivity and invasion of GBM.
Appendix
Available only for authorised users
Literature
1.
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996PubMedCrossRef
2.
Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110PubMedPubMedCentralCrossRef
3.
Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466PubMedCrossRef
4.
Van Meir EG, Hadjipanayis CG, Norden AD et al (2010) Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60(3):166–193PubMedPubMedCentralCrossRef
5.
6.
Nakamura F, Stossel TP, Hartwig JH (2011) The filamins: organizers of cell structure and function. Cell Adhes Migr 5(2):160–169CrossRef
7.
Berrou E, Adam F, Lebret M et al (2017) Gain-of-function mutation in filamin A potentiates platelet integrin alphaIIbbeta3 activation. Arterioscler Thromb Vasc Biol 37(6):1087–1097PubMedCrossRef
8.
Gorlin JB, Yamin R, Egan S et al (1990) Human endothelial actin-binding protein (ABP-280, nonmuscle filamin): a molecular leaf spring. J Cell Biol 111(3):1089–1105PubMedCrossRef
9.
van der Flier A, Sonnenberg A (2001) Structural and functional aspects of filamins. Biochem Biophys Acta 1538(2–3):99–117PubMedCrossRef
10.
Deng W, Lopez-Camacho C, Tang JY et al (2012) Cytoskeletal protein filamin A is a nucleolar protein that suppresses ribosomal RNA gene transcription. Proc Natl Acad Sci USA 109(5):1524–1529PubMedCrossRefPubMedCentral
11.
Mooso BA, Vinall RL, Tepper CG et al (2012) Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization. Endocr Relat Cancer 19(6):759–777PubMedCrossRef
12.
Planaguma J, Minsaas L, Pons M et al (2012) Filamin A-hinge region 1-EGFP: a novel tool for tracking the cellular functions of filamin A in real-time. PLoS ONE 7(8):e40864PubMedPubMedCentralCrossRef
13.
Liu T, Mendes DE, Berkman CE (2014) Prolonged androgen deprivation leads to overexpression of calpain 2: implications for prostate cancer progression. Int J Oncol 44(2):467–472PubMedCrossRef
14.
15.
Savoy RM, Ghosh PM (2013) The dual role of filamin A in cancer: can't live with (too much of) it, can't live without it. Endocr Relat Cancer 20(6):R341–356PubMedPubMedCentralCrossRef
16.
17.
Robertson SP, Twigg SR, Sutherland-Smith AJ et al (2003) Localized mutations in the gene encoding the cytoskeletal protein filamin A cause diverse malformations in humans. Nat Genet 33(4):487–491PubMedCrossRef
18.
Saido TC, Sorimachi H, Suzuki K (1994) Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J 8(11):814–822PubMedCrossRef
19.
Ray SK, Wilford GG, Crosby CV et al (1999) Diverse stimuli induce calpain overexpression and apoptosis in C6 glioma cells. Brain Res 829(1–2):18–27PubMedCrossRef
20.
Ray SK, Fidan M, Nowak MW et al (2000) Oxidative stress and Ca2+ influx upregulate calpain and induce apoptosis in PC12 cells. Brain Res 852(2):326–334PubMedCrossRef
21.
Yang Z, Lin F, Robertson CS et al (2014) Dual vulnerability of TDP-43 to calpain and caspase-3 proteolysis after neurotoxic conditions and traumatic brain injury. J Cereb Blood Flow Metab 34(9):1444–1452PubMedPubMedCentralCrossRef
22.
Catzavelos C, Bhattacharya N, Ung YC et al (1997) Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3(2):227–230PubMedCrossRef
23.
Chappuis PO, Donato E, Goffin JR et al (2005) Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol 16(5):735–742PubMedCrossRef
24.
Shao QQ, Zhang TP, Zhao WJ et al (2016) Filamin A: insights into its exact role in cancers. Pathol Oncol Res POR 22(2):245–252PubMedCrossRef
25.
Fucini P, Koppel B, Schleicher M et al (1999) Molecular architecture of the rod domain of the Dictyostelium gelation factor (ABP120). J Mol Biol 291(5):1017–1023PubMedCrossRef
26.
Krebs K, Ruusmann A, Simonlatser G et al (2015) Expression of FLNa in human melanoma cells regulates the function of integrin alpha1beta1 and phosphorylation and localisation of PKB/AKT/ERK1/2 kinases. Eur J Cell Biol 94(12):564–575PubMedCrossRef
27.
Sun GG, Lu YF, Zhang J et al (2014) Filamin A regulates MMP-9 expression and suppresses prostate cancer cell migration and invasion. Tumour Biol 35(4):3819–3826PubMedCrossRef
28.
Xu Y, Bismar TA, Su J et al (2010) Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J Exp Med 207(11):2421–2437PubMedPubMedCentralCrossRef
29.
Zhang K, Zhu T, Gao D et al (2014) Filamin A expression correlates with proliferation and invasive properties of human metastatic melanoma tumors: implications for survival in patients. J Cancer Res Clin Oncol 140(11):1913–1926PubMedCrossRefPubMedCentral
30.
Wieczorek K, Wiktorska M, Sacewicz-Hofman I et al (2017) Filamin A upregulation correlates with Snail-induced epithelial to mesenchymal transition (EMT) and cell adhesion but its inhibition increases the migration of colon adenocarcinoma HT29 cells. Exp Cell Res 359(1):163–170PubMedCrossRef
31.
Wensheng D (2012) Cytoskeletal protein filamin A is a nucleolar protein that suppresses ribosomal RNA gene transcription. Proc Natl Acad Sci USA 5(109):1524–1529
32.
Storr SJ, Carragher NO, Frame MC et al (2011) The calpain system and cancer. Nat Rev Cancer 11(5):364–374PubMedCrossRef
33.
34.
Chen J, Wu Y, Zhang L et al (2019) Evidence for calpains in cancer metastasis. J Cell Physiol 234(6):8233–8240PubMedCrossRef
35.
Liu J, Liu MC, Wang KK (2008) Calpain in the CNS: from synaptic function to neurotoxicity. Sci Signal 1(14):re1PubMedCrossRef
36.
Su Y, Cui Z, Li Z et al (2006) Calpain-2 regulation of VEGF-mediated angiogenesis. FASEB J 20(9):1443–1451PubMedCrossRef
37.
Bramhall SR, Neoptolemos JP, Stamp GW et al (1997) Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 182(3):347–355PubMedCrossRef
38.
Fillmore HL, VanMeter TE, Broaddus WC (2001) Membrane-type matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion. J Neurooncol 53(2):187–202PubMedCrossRef
39.
Pornchai OC, Rhys-Evans PH, Eccles SA (2001) Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 127(7):813–820
40.
Theret N, Musso O, Turlin B et al (2001) Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 34(1):82–88PubMedCrossRef
41.
Kallakury BV, Karikehalli S, Haholu A et al (2001) Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7(10):3113–3119PubMed
42.
Tanaka K, Iwamoto Y, Ito Y et al (1995) Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080. Cancer Res 55(13):2927–2935PubMed
Metadata
Title
Calpain suppresses cell growth and invasion of glioblastoma multiforme by producing the cleavage of filamin A
Authors
Lin Cai
Qun Li
Wenfeng Li
Chengde Wang
Ming Tu
Zhangzhang Zhu
Zhipeng Su
Xianghe Lu
Publication date
01-06-2020
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 6/2020
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-020-01636-7

Other articles of this Issue 6/2020

International Journal of Clinical Oncology 6/2020 Go to the issue

Original Article

Fertility preservation and fulfillment of parenthood after treatment of hematological malignancies: results from the ‘Aftercare in Blood Cancer Survivors’ (ABC) study

Original Article

Comparison of involved field radiotherapy and elective nodal irradiation in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer

Original Article

Prognostic significance of β2-adrenergic receptor expression in patients with surgically resected colorectal cancer

Invited Review Article

Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems

Original Article

Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survival

Original Article

Extent of neck dissection for patients with clinical N1 oral cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits